Obesity Market Summary

• According to DelveInsight’s analysis, obesity market size was nearly USD 16 billion in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• In 2025, the total number of prevalent cases of obesity in the 7MM was approximately 190 million. Among the 7MM countries, the US accounted for the highest number of prevalent cases.
• The total market size of obesity in the US in 2025 was approximately USD 13 billion, this is anticipated to grow by 2036, driven by the rising obesity burden, increasing recognition of obesity as a chronic disease requiring long-term pharmacological management.
• The obesity treatment landscape is highly concentrated around Novo Nordisk and Eli Lilly, with their incretin-based therapies setting the benchmark for efficacy and commercial performance. SAXENDA (liraglutide) and WEGOVY (semaglutide) from Novo Nordisk, together with ZEPBOUND (tirzepatide) from Eli Lilly, remain key pillars of the pharmacological market. Both companies are also pursuing next-generation oral formulations and multi-agonist therapies, reflecting an ongoing shift toward more convenient and potentially more effective treatment options.
• The obesity pipeline is rapidly evolving beyond established GLP-1 therapies, with a growing number of investigational assets designed to improve the magnitude, durability, and convenience of weight loss. Emerging candidates such as RGT-075 (Regor Therapeutics) and enicepatide (CT-388; Roche/Carmot Therapeutics) represent diverse next-generation approaches. Collectively, these programs could broaden the therapeutic landscape, address limitations associated with current incretin therapies, and intensify competition across the obesity market.
• In December 2025, Novo Nordisk announced FDA approval of oral semaglutide 25 mg (WEGOVY) as the first oral GLP-1 receptor agonist for weight management. Novo subsequently expanded access through Medicare Part D and its Bridge program, while international launches in the UK and UAE and approval in the EU supported rapid adoption.
• In the UK, approximately 300,000 patients were estimated to be using the WEGOVY pill within three weeks of launch, suggesting potential to expand the treated obesity population beyond a simple shift from injectable to oral therapy.
• One critical unmet need in obesity management is the development of longer-acting therapies. While innovative treatments are expected to enter the market over the next decade, there remains a significant opportunity for pharmaceutical companies to advance drugs that require less frequent administration. Currently, even the lowest-frequency treatments necessitate weekly injections, which can be a barrier for many patients.

Obesity Market size and forecast

• 2025 Obesity Market Size in the 7MM: ~USD 16 billion
• Obesity Growth Rate (2022-2036): ~27% CAGR

DelveInsight’s “Obesity Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding of obesity, historical and forecasted epidemiology, as well as the OBESITY market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The obesity market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, obesity patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment and growth rate projections (Historical & Forecast 2022–2036) across the 7MM regions. The report highlights key unmet medical needs in obesity and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Obesity Disease Understanding

Obesity Overview

Obesity is a chronic complex disease defined by excessive fat deposits that can impair health. Obesity can lead to increased risk of type 2 diabetes and heart disease. It can affect bone health and reproduction, and it increases the risk of certain cancers. Overweight and obesity result from an imbalance of energy intake (diet) and energy expenditure (physical activity). In most cases, obesity is a multifactorial disease due to obesogenic environments, psycho-social factors, and genetic variants. In some patients, single major causes like medications, diseases, or genetic syndromes are identified.

Obesity Diagnosis

The diagnosis of overweight and obesity is made by measuring people’s weight and height and by calculating the Body Mass Index (BMI): weight (kg)/height² (m²). The body mass index is a surrogate marker of fatness and additional measurements, such as the waist circumference, can help the diagnosis of obesity. The BMI categories for defining obesity vary by age and gender in infants, children, and adolescents.

Further details related to country-based variations are provided in the report...

Current Obesity Treatment Landscape

Effective therapeutic strategies include lifestyle modifications, pharmacotherapy, and bariatric surgery. Lifestyle changes can result in up to 10% weight reduction, though this may be insufficient for many patients dealing with severe obesity. Pharmacotherapy and bariatric surgery, therefore, represent critical adjuncts to lifestyle interventions, especially in cases where significant weight loss is required to mitigate obesity-related complications. Pharmacological options have expanded over the years and include Glucagon-like Peptide-1 (GLP-1) receptor agonists, dual agonists that target both GLP-1 and Glucose-dependent Insulinotropic Polypeptide Receptors (GIPR), pancreatic lipase inhibitors, and sympathomimetics. Additionally, combination therapies, such as sympathomimetic-anticonvulsant or opioid receptor antagonist-dopamine/noradrenaline reuptake inhibitors, offer diverse mechanisms of action to address the multifaceted nature of obesity.

The obesity market is entering a period of significant diversification, driven by a shift from traditional lifestyle interventions and earlier-generation pharmacotherapies toward highly effective incretin-based treatments. Novo Nordisk and Eli Lilly currently hold leading positions, with semaglutide (WEGOVY) and liraglutide (SAXENDA) from Novo Nordisk and tirzepatide (ZEPBOUND) from Eli Lilly forming key components of the branded obesity treatment landscape.

Further details related to country-based variations are provided in the report...

Obesity Unmet Needs

The section “unmet needs of obesity” outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Need for longer-acting therapies

2. Demand for safer and more effective obesity medications

3. Limited access and reimbursement for obesity treatments

4. Need for updated treatment guidelines in obesity management and others…

Note: Comprehensive unmet needs insights in obesity and their strategic implications are provided in the full report...

Obesity Epidemiology

The Obesity epidemiology section provides insights about the historical and current Obesity patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Obesity market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings from Obesity Epidemiological Analysis and Forecast

• According to DelveInsight’s analysis, the United States accounted for approximately 60% of the total prevalent obesity cases across the 7MM in 2025, reflecting its substantial disease burden and positioning the US as the largest market within the assessed geographies.
• In 2025, approximately 7 million children aged 5–19 years in the US were living with obesity, underscoring the significant pediatric disease burden and the growing need for effective prevention and treatment strategies targeting younger populations.
• Among the EU4 and the UK, Germany recorded the highest number of prevalent obesity cases in 2025, at approximately 18 million. The large affected population highlights Germany as a key market for obesity management and represents considerable potential for the adoption of effective pharmacological therapies.
• Japan is witnessing a gradual increase in treated obesity cases, supported by growing disease awareness and the expanding availability of treatment options. In 2025, Japan had approximately 150,000 treated adult cases and around 180 treated pediatric cases. The continued increase in treated populations is expected to support greater demand for obesity therapies as diagnosis, treatment-seeking, and access to pharmacological interventions improve.

Obesity Epidemiology Segmentation

• Total Prevalent Cases of Obesity
• Total Diagnosed Prevalent Cases of Obesity
• Severity-specific Diagnosed Prevalent Cases of Obesity by BMI
• Comorbidities-specific Diagnosed Prevalent Cases of Obesity
• Total Treated Cases of Obesity

Recent Developments in the Obesity Treatment Landscape:

• In Sep 2026, Eli Lilly presented clinical data showing that its investigational triple GIP/GLP-1/glucagon receptor agonist, retatrutide, delivered substantial weight loss and A1C reductions in clinical trials. The novel molecule demonstrated significant metabolic improvements in adults with obesity and type 2 diabetes, underscoring its potential as a highly effective single-agent multi-receptor therapy capable of addressing both body weight management and glycemic control simultaneously.
• In Sep 2026, Eli Lilly and Company launched the "Change the Course" commitment, a global initiative aiming to eliminate treatment gaps for diabetes and obesity in low- and middle-income countries (LMICs). The program seeks to expand access so that as many individuals in resource-limited settings can access Lilly's innovative diabetes and obesity treatments as in high-income countries by 2040. Through collaborations with international health organizations, Lilly plans to adapt trial designs, streamline regional regulatory filings, and strengthen primary healthcare infrastructure through community health worker training and digital diagnostics.
• In September 2026, Menu-Order AI Launched Daily GLP-1 Habit Tracker: Menu-Order AI introduced "Daily GLP-1 Habits," a feature created with Medical Advisor Dr. Leigh-Anne Dale to help users track nutrition, macros, movement, and behavioral habits alongside medication. The launch aligns with expanded Medicare and Medicaid GLP-1 coverage programs (such as the Medicare GLP-1 Bridge and BALANCE model) and global WHO guidelines emphasizing structured lifestyle support alongside GLP-1 weight-loss medications. The tool allows patients to log progress and generate monthly reports to share directly with their healthcare providers.
• In Sep 2026, Metavia announced preclinical data supporting DA-1726's ability to reduce waist circumference in obesity models. The dual GLP-1/GIP receptor agonist demonstrated superior reduction in visceral fat compared to tirzepatide at equivalent doses. Researchers attributed this to enhanced metabolic lipid clearance and targeted adipose tissue tissue-remodeling, supporting its continued clinical progression for metabolic disorders.
• In Sep 2026, Orderly Wellness partnered with Veo Health to provide GLP-1 weight-loss patients with comprehensive health tracking, offering personalized digital support and body composition metrics alongside medication therapy.
• In Sep 2026, Ascletis Pharma initiated a Phase 1 clinical study in the U.S. evaluating ASC36, an oral amylin receptor peptide agonist, for chronic weight management. Designed to target satiety pathways and slow gastric emptying, the candidate offers a potential non-incretin mechanism for sustained fat loss. The trial will assess the safety, tolerability, pharmacokinetics, and preliminary weight-loss efficacy of ASC36 in healthy and overweight participants.
• In Sep 2026, MasterClass launched "Understanding GLP-1s and Weight Loss," an educational course designed as companion guidance for patients receiving GLP-1 receptor agonist prescriptions. Led by medical experts, the curriculum covers metabolic science, nutrition, muscle preservation, side-effect management, and long-term behavioral strategies. The platform aims to bridge the gap between clinical prescription and daily lifestyle adherence, helping patients navigate the physical and psychological transitions associated with medical weight loss.
• In Sep 2026, Ascletis Pharma dosed the first participant in its global Phase 3 clinical program evaluating ASC30, an oral small-molecule GLP-1 receptor agonist, for chronic weight management. The program includes the AURORA-1 and AURORA-2 trials testing once-daily maintenance doses over 72 weeks in 4,600 adults with obesity or overweight, with and without type 2 diabetes. Topline data are expected in Q3 2028, positioning ASC30 as a potential leading oral alternative to injectable obesity medications.
• In Sep 2026, Eli Lilly announced positive Phase 3b data for the combined use of Taltz (ixekizumab) and Zepbound (tirzepatide) in adults with psoriatic disease and obesity. The combination delivered superior and durable efficacy at one year compared to Taltz alone, significantly improving both joint and skin disease activity while achieving substantial weight loss. The findings establish a comprehensive treatment approach that simultaneously targets systemic inflammation and obesity to improve long-term disease control and overall health outcomes in this patient population.
• In September 2026, Roche announced positive topline results from CT-388-104, a Phase II clinical trial evaluating enicepatide (CT-388), in adults living with overweight or obesity. In the study, enicepatide met both primary endpoints, delivering dose-dependent and clinically meaningful reductions in body weight at 48 weeks.
• In September 2026, Lilly announced that the ACHIEVE program data for FOUNDAYO would be presented at EASD 2026, including cardiovascular and metabolic findings from ACHIEVE-4 in adults with obesity/overweight and type 2 diabetes.
• In June 2026, Roche presented late-breaking Phase II data on enicepatide (CT-388) at the American Diabetes Association’s 2026, demonstrating its efficacy and safety in individuals with overweight or obesity.
• In January 2025, Regor Therapeutics announced topline results from its Phase IIa clinical trial for RGT-075, a leading oral once-daily small molecule full agonist of GLP-1 receptor.

Obesity Drug Analysis & Competitive Landscape

The obesity drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III Obesity clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the obesity treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the obesity therapeutics market.

Approved Therapies for Obesity

Orforglipron (FOUNDAYO): Eli Lilly

Orforglipron (FOUNDAYO) is an oral, once-daily GLP-1 receptor agonist developed by Eli Lilly and approved by the US FDA, for use in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain long-term weight reduction in adults with obesity or adults with overweight and at least one weight-related comorbidity. Orforglipron is administered orally with or without food, with an approved maximum dose of 17.2 mg once daily, and represents a new oral GLP-1 treatment option for chronic weight management.

• In April 2026, Eli Lilly and Company announced that the US FDA approved FOUNDAYO for adults with obesity or overweight with weight-related comorbidities.

Note: Detailed marketed therapies assessment will be provided in the final report...

Obesity Pipeline Analysis

Enicepatide (CT-388): Roche/Carmot Therapeutics

Enicepatide (CT-388) is an investigational once-weekly subcutaneous dual GLP-1/GIP receptor agonist for obesity and associated comorbidities, including type 2 diabetes. It features biased signaling with minimal ß-arrestin recruitment, supporting sustained receptor activity. CT-388 was designed to have potent activity on both the GLP-1 and GIP receptors but with minimal to no ß-arrestin recruitment on either receptor. This biased signaling significantly minimizes receptor internalization and consequent desensitization, which is expected to lead to prolonged pharmacological activity. It is expected to be filed in 2028.

Note: Detailed emerging therapies assessment will be provided in the final report...

Obesity Key Players, Market Leaders and Emerging Companies

• Eli Lilly
• Novo Nordisk
• Currax Pharmaceuticals
• Roche
• Regor Therapeutics
• D&D Pharmatech/Pfizer, and others

Obesity Market Outlook

The obesity market outlook remains highly positive, driven by the growing adoption of highly effective incretin-based therapies and continued pipeline innovation. Semaglutide (WEGOVY) and tirzepatide (ZEPBOUND) are expected to remain key market leaders, supported by substantial weight-loss efficacy and expanding indications. Established therapies such as orlistat (XENICAL), and phentermine/topiramate (QSYMIA) are likely to retain a role in specific patient populations. Meanwhile, emerging therapies could further intensify competition and expand treatment options, supporting sustained growth of the obesity market.

• In 2025, the obesity market size in the US was around USD 13 billion. This figure is expected to grow significantly with the introduction of emerging therapies.
• The total market size of EU4 and the UK was estimated to be more than USD 2.5 billion in 2025.
• Among EU4 and the UK, Germany accounted for the highest market share with approximately USD 720 million in 2025.
• In 2025, the total market size of obesity was approximately USD 70 million in Japan, which is anticipated to increase during the forecast period (2026–2036).
• Drug Class/Insights into Leading Emerging Therapies in Obesity (2022–2036 Forecast)

The obesity treatment landscape includes small molecules, peptides, recombinant DNA therapies, monoclonal antibodies, GLP-1 receptor agonists, dual/multi-receptor incretin agonists, and combination therapies, with increasing emphasis on efficacy, tolerability, and convenient administration. Small molecules remain important due to their oral convenience and established mechanisms, while peptide and recombinant DNA-based therapies dominate the newer incretin landscape. Monoclonal antibodies and other biologic approaches represent additional emerging modalities, although their role in obesity remains comparatively limited.

• Small molecules remain an important drug class in obesity treatment, particularly through centrally acting and gastrointestinal mechanisms that regulate appetite, satiety, and nutrient absorption. Established therapies such as orlistat (XENICAL) and phentermine exemplify this approach, although their weight-loss efficacy is generally more modest than that of newer incretin-based therapies.
• The emergence of oral GLP-1 therapies, particularly orforglipron (FOUNDAYO) and the oral semaglutide (WEGOVY pill), is expected to significantly increase the importance of small molecules in the obesity market by combining the convenience of oral administration with the higher efficacy associated with incretin-based treatment.

Obesity Drug Uptake

This section focuses on the uptake rate of potential Obesity drugs expected to be launched in the market during the forecast period (2026–2036). The analysis covers the obesity drug’s uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

Following its US approval and launch, orforglipron (FOUNDAYO) is positioned for fast market uptake, with its once-daily oral formulation offering a potentially differentiated and more convenient alternative to other obesity therapies.

Detailed insights of emerging therapies' drug uptake is included in the report…

Market Access and Reimbursement of therapies in Obesity

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

EU4 and the UK

As the obesity market transitions toward broader adoption and oral therapies, manufacturers are increasingly leveraging affordability programs to improve patient access. While Injectable WEGOVY continues to carry a US list price of approximately USD 1,349 per month, although commercial insurance and cash-pay programs can reduce patient costs to as low as USD 25 and USD 349 per month, respectively.

Lilly's ZEPBOUND is offered through its Self-Pay Journey Program at USD 299–449 per month depending on dose, despite list prices ranging from approximately USD 499 to USD 1,086 per month. Meanwhile, the newly launched oral WEGOVY and Lilly's oral GLP-1 therapy, orforglipron (FOUNDAYO), have entered the market with self-pay prices starting at USD 149 per month, with most higher-dose regimens priced between USD 299 and USD 349 per month, reflecting a broader industry push to improve accessibility as the obesity treatment landscape expands.

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

NOTE: Further Details are provided in the final report...

Obesity Therapies Price Scenario & Trends

Pricing and analogue assessment of obesity therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Pricing of Obesity Approved Drugs

• The estimated annual treatment cost of semaglutide (WEGOVY) in the US was approximately USD 12,505 in 2025, reflecting the substantial cost associated with long-term obesity management.

Industry Experts and Physician Views for Obesity

To keep up with obesity market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the obesity emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in obesity, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 10+ KOLs to gather insights at country level. Centers such as the Princeton Spine & Joint Center, University Hospital Giessen, and Saitama Medical University etc. were contacted.

Their opinion helps understand and validate current and emerging obesity therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in obesity.

Obesity Report Qualitative Analysis: SWOT and Attribute Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and attribute analysis.

In the SWOT analysis of obesity, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provide attribute analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Obesity Market Report

• The report covers a segment of key events, an executive summary, a descriptive overview of obesity, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the obesity market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM obesity market.

Obesity Market Report Insights

• Obesity Patient Population Forecast
• Obesity Therapeutics Market Size
• Obesity Pipeline Analysis
• Obesity Market Size and Trends
• Obesity Market Opportunity (Current and Forecasted)

Obesity Market Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI) - enabled Market Research Report
• 11-year forecast
• Obesity Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Obesity Treatment Addressable Market (TAM)
• Obesity Competitive Landscape
• Obesity Major Companies Insights
• Obesity Price Trends and Analogue Assessment
• Obesity Therapies Drug Adoption/Uptake
• Obesity Therapies Peak Patient Share analysis

Obesity Market Report Assessment

• Obesity Current Treatment Practices
• Obesity Unmet Needs
• Obesity Clinical Development Analysis
• Obesity Emerging Drugs Product Profiles
• Obesity Market Attractiveness
• Obesity Qualitative Analysis (SWOT and Attribute analysis)
• Obesity Market Drivers
• Obesity Market Barriers

FAQs Related to the Obesity Market Report:

Obesity Market Insights

• What was the obesity market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of obesity?
• What are the disease risks, burdens, and unmet needs of obesity? What will be the growth opportunities across the 7MM concerning the obesity patient population?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of obesity? What are the current guidelines for treating obesity in the US, Europe, and Japan?

Reasons to Buy Obesity Market Forecast Report:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the obesity market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis, ranking of class-wise potential current, and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.